NCT07191431View on ClinicalTrials.gov

A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

September 2, 2027

Study Completion Date

September 2, 2029

Conditions

Lymphoma Cns

Interventions

DRUG

Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide

"* Orelabrutinib 150mg qd + Selinexor 40mg qw~* Combined chemotherapy (choose one):~ * MTX 3.5g/m² IV d0~ * Temozolomide 150mg/m² PO d1-5~ * Thiotepa 40mg/m² IV d3~* Every 3 weeks for 6 cycles"

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT07191431 - A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） | Biotech Hunter | Biotech Hunter